本文测定了１２例高血压病患者经伊拉地平（Ｉｓｒａｄｉｐｉｎｅ）（１．２５ｍｇ～２．５ｍｇ，１日２次）治疗８周前后和１０例健康对照者的血小板聚集性（ＰＡｇ）、血浆组织型纤溶酶原激活剂（ｔ－ＰＡ）及其抑制物（ＰＡＩ）活性。结果表明，高血压组ＰＡｇ、ＰＡＩ活性明显高于对照组，ｔ－ｐＡ活性显著低于对照组；伊拉地平治疗后，ＰＡｇ、ＰＡＩ活性显著降低，ｔ－ＰＡ活性显著升高。本文提示：高血压病患者存在血小板功能亢进和纤溶活性降低，伊拉地平能够抑制血小板聚集，增强纤溶活性，在防治心脑血管并发症方面具有重要意义。 This article measured platelet aggregation (PAg) in 12 hypertensive patients before and after 8 weeks of treatment with Isradipine (1.25 mg to 2.5 mg twice daily) and 10 healthy controls, Type plasminogen activator (t-PA) and its inhibitor (PAI) activity. The results showed that the activity of PAg and PAI in hypertension group was significantly higher than that in control group, the activity of t-pA was significantly lower than that in control group. The activity of PAg and PAI was significantly decreased and t-PA activity was significantly increased after treatment with ilabedon. This article suggests that: Hypertension patients with impaired platelet function and fibrinolytic activity is reduced, the Iraqi horizon can inhibit platelet aggregation and enhance fibrinolytic activity in the prevention and treatment of cardiovascular and cerebrovascular complications is of great significance.